MaxCyte Overview
- Founded
-
1998

- Status
-
Public
- Employees
-
84

- Stock Symbol
-
MXCT

- Share Price
-
$5.76
- (As of Friday Closing)
MaxCyte General Information
Description
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
Contact Information
- 22 Firstfield Road
- Suite 110
- Gaithersburg, MD 20878
- United States
MaxCyte Timeline
MaxCyte Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.76 | $5.87 | $3.46 - $17.09 | $586M | 102M | 47.2K | -$0.20 |
MaxCyte Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 274,360 | 772,035 | 523,497 | 79,149 |
Revenue | 41,486 | 33,894 | 26,169 | 21,621 |
EBITDA | (18,479) | (16,765) | (10,009) | (11,806) |
Net Income | (19,882) | (19,082) | (11,816) | (12,895) |
Total Assets | 289,777 | 284,120 | 51,780 | 29,985 |
Total Debt | 14,492 | 5,682 | 6,966 | 7,211 |
MaxCyte Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
MaxCyte Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
MaxCyte Comparisons
Industry
MaxCyte Competitors (25)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
PPA Research Group | Private Equity-Backed | Johnson City, TN | 000000000000 | |||
0000000000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
0000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000 - 000 | 00000 |
00000 | Corporation | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
00000000 | Formerly VC-backed | San Diego, CA | 00000 | 00000 | 000000&0 |
MaxCyte Patents
MaxCyte Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210348109-A1 | Systems and methods for electroporation | Pending | 11-May-2020 | 000000000 | |
CA-2982759-A1 | Methods and compositions for modifying genomic dna | Pending | 13-Apr-2015 | 0000000000 | |
EP-3283635-A1 | Methods and compositions for modifying genomic dna | Granted | 13-Apr-2015 | 0000000000 | |
JP-2018512162-A | Methods and compositions for modifying genomic dna | Granted | 13-Apr-2015 | 0000000000 | |
US-20180112235-A1 | Methods and compositions for modifying genomic dna | Pending | 13-Apr-2015 | C12N15/907 |
MaxCyte Executive Team (18)
MaxCyte Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Arthur Mandell | Self | Board Member | 000 0000 |
Douglas Doerfler | MaxCyte | Founder, Chief Executive Officer, President & Board Member | 000 0000 |
J. Thompson Ph.D | MaxCyte | Chairman & Board Member | 000 0000 |
John Johnston | MaxCyte | Board Member | 000 0000 |
Rekha Hemrajani | Self | Board Member | 000 0000 |
MaxCyte Signals
MaxCyte Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|